Boston Scientific spinal cord trial delayed after patent ruling
Courtesy | Boston Scientific
Boston Scientific's headquarters are located in Marlborough.
Boston Scientific has no immediate plans to launch a high-frequency spinal cord stimulation product in the wake of recent rulings in a patent infringement case.
In a joint case management statement filed last week, Boston Scientific said it has no plans to launch a product being used in a clinical study. That study will be delayed into mid-2019.
The statement comes after a U.S. federal court ruled that Boston Scientific was not infringing upon California-based Nevro’s stimulation product since the device is only in trial stage, but found six claims in three Nevro products are eligible.
The joint statement proposes a dismissal of declaratory judgement claims outstanding in the dispute because Boston Scientific said it doesn't plan to launch a high-frequency product in the U.S.
Nevro’s 2016 complaint came after Boston Scientific announced plans to release results of a high-frequency spinal cord stimulation study in 2017 with the belief that the company would seek U.S. approval for such a product.
Since that compliant, Boston Scientific’s study has been extended and no product has been launched.
Nevro still upholds that its patents would preclude Boston Scientific from launching a high-frequency system. The company said it plans to appeal the court's’ rulings that Boston Scientific is not infringing.
WBJ Web Partners
Most Recent
Most Recent
0 Comments